Workflow
中国LSHC生命科学与医疗行业调查报告
Deloitte·2025-04-29 01:05

Investment Rating - The report indicates a generally optimistic outlook for the Chinese LSHC industry, with a significant portion of local players expressing ambition and optimism for growth in 2025 [25]. Core Insights - The Chinese LSHC industry is experiencing increased competition and a shift towards cautious investment strategies due to changing market dynamics and regulatory environments [28][55]. - Local players are increasingly focusing on innovation and market access, with a notable emphasis on adapting to new regulatory requirements and leveraging digital technologies [46][44]. - The importance of value propositions is highlighted, particularly in the context of ongoing healthcare payment reforms and the shrinking economic value window for innovative assets [31][34]. Summary by Sections Industry Outlook and Considerations - The overall economic value cycle remains a critical factor for stakeholders, with a focus on "going out" strategies and increased business development efforts from both local and foreign participants [21]. - A significant percentage of respondents (54%) believe their business performance in 2024 will exceed that of 2023, indicating cautious optimism despite challenges [18]. Regulatory and Technological Impacts - The evolving regulatory framework in China is becoming increasingly critical for both local and foreign companies, with nearly half of respondents noting increased constraints due to data privacy and export regulations [38][41]. - The report emphasizes the need for organizations to adapt their talent models and invest in digital capabilities to remain competitive in the changing landscape [44][46]. New Business Investment Strategies - There is a notable shift towards investing in new market channels beyond traditional hospital routes, with 76% of respondents indicating deployment of new channel investments [50]. - The relaxation of foreign investment regulations has intensified local competition, prompting organizations to increase localization investments across various areas, including R&D and clinical trials [52][54]. Market Preferences and Strategic Focus - The report identifies that the market's focus has shifted, with internal competition increasing significantly, leading to a more cautious approach to investment in China [28]. - The importance of market size and patient needs continues to be a primary consideration for businesses entering the Chinese market, alongside government-driven initiatives [55][56].